Male contraception: History and development

Urologic Clinics of North America

Volumn 41, Issue 1, 2014, Pages 145-161

  Kogan, Paul ^a   Wald, Moshe ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Condoms; History; Male contraception; Testosterone; Vasectomy

Indexed keywords

CONDOMS; HISTORY; MALE CONTRACEPTION; TESTOSTERONE; VASECTOMY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANDROGENS; ANIMALS; CONDOMS; CONTRACEPTION; CONTRACEPTIVE AGENTS, MALE; DITERPENES; DRUG IMPLANTS; EPOXY COMPOUNDS; ETHNIC GROUPS; GONADOTROPIN-RELEASING HORMONE; GOSSYPOL; HUMANS; IMMUNOLOGIC TECHNIQUES; INDAZOLES; MALE; NORETHINDRONE; PHENANTHRENES; PROGESTINS; SPERMATOGENESIS; SPERMATOZOA; TESTOSTERONE; VASECTOMY;

EID: 84888307312     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2013.08.012     Document Type: Review

References (150)

1. World contraceptive use 2009. United Nations, Department of Economic and Social Affairs, Population Division (2009). Available at:. Accessed March 17, 2013. http://www.un.org/esa/population/publications/WCU2009/WCP_2009/Data.html.
2. Grady W.R., Tanfer K., Billy J.O., et al. Men's perceptions of their roles and responsibilities regarding sex, contraception and childrearing. Fam Plann Perspect 1996, 28:221-226.
3. Heinemann K., Saad F., Wiesemes M., et al. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 2005, 20:549-556.
4. Youssef H. The history of the condom. JR Soc Med 1993, 86:226-228.
5. Trussell J. Contraceptive failure in the United States. Contraception 2011, 83:397-404.
6. Kost K., Singh S., Vaughan B., et al. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 2008, 77:10-21.
7. Sheynkin Y.R. History of vasectomy. Urol Clin North Am 2009, 36:285-294.
8. Some of the indications for vasectomy. JAm Med Assoc 1900, 35:1412.
9. Castration and vasectomy in hypertrophy of the prostate. Lancet 1897, 149:1286.
10. Ochsner A.J. Surgical treatment of habitual criminals. JAm Med Assoc 1899, 32:867-868.
11. Pile J.M., Barone M.A. Demographics of vasectomy-USA and international. Urol Clin North Am 2009, 36:295-305.
12. Chandra A., Martinez G.M., Mosher W.D., et al. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 23 2005, (25):1-160.
13. Anderson J.E., Jamieson D.J., Warner L., et al. Contraceptive sterilization among married adults: national data on who chooses vasectomy and tubal sterilization. Contraception 2012, 85:552-557.
14. Eisenberg M.L., Lipshultz L.I. Estimating the number of vasectomies performed annually in the United States: data from the National Survey of Family Growth. JUrol 2010, 184:2068-2072.
15. Barone M.A., Hutchinson P.L., Johnson C.H., et al. Vasectomy in the United States, 2002. JUrol 2006, 176:232-236.
16. Sharlip I.D., Belker A.M., Honig S., et al. Vasectomy: AUA guideline. JUrol 2012, 188(Suppl 6):2482-2491.
17. Awsare N.S., Krishnan J., Boustead G.B., et al. Complications of vasectomy. Ann R Coll Surg Engl 2005, 87:406-410.
18. Leslie T.A., Illing R.O., Cranston D.W., et al. The incidence of chronic scrotal pain after vasectomy: a prospective audit. BJU Int 2007, 100:1330-1333.
19. Heckel N.J. Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 1939, 40:658-659.
20. Nieschlag E., Zitzmann M., Kamischke A. Use of progestins in male contraception. Steroids 2003, 68:965-972.
21. Wu F.C. Hormonal approaches to male contraception: approaching reality. Mol Cell Endocrinol 2006, 250:2-7.
22. Turner L., Conway A.J., Jiminez M., et al. Contraceptive efficacy of a depot progestin and androgen combination in men. JClin Endocrinol Metab 2003, 88:4659-4667.
23. Amory J.K., Page S.T., Anawalt B.D., et al. Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception 2007, 75:218-223.
24. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 1996, 65:821-829.
25. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 1990, 336:955-959.
26. Ilani N., Liu P.Y., Swerdloff R.S., et al. Does ethnicity matter in male hormonal contraceptive efficacy?. Asian J Androl 2011, 13:579-584.
27. Kinniburgh D., Zhu H., Cheng L., et al. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod 2002, 17:1490-1501.
28. Liu P.Y., Swerdloff R.S., Christenson P.D., et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 2006, 367:1412-1420.
29. Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. World Health Organization. Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 1993, 60:1062-1068.
30. Gu Y., Liang X., Wu W., et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. JClin Endocrinol Metab 2009, 94:1910-1915.
31. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65:275-281.
32. Lue Y., Wang C., Cui Y., et al. Levonorgestrel enhances spermatogenesis suppression by testosterone with greater alteration in testicular gene expression in men. Biol Reprod 2009, 80:484-492.
33. Bebb R.A., Anawalt B.D., Christensen R.B., et al. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. JClin Endocrinol Metab 1996, 81:757-762.
34. Wu F.C., Balasubramanian R., Mulders T.M., et al. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. JClin Endocrinol Metab 1999, 84:112-122.
35. Meriggiola M.C., Bremner W.J., Costantino A., et al. Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum Reprod 1998, 13:1225-1229.
36. Soufir J.C., Meduri G., Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod 2011, 26:1708-1714.
37. Guerin J.F., Rollet J. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 1988, 11:187-199.
38. Zitzmann M., Erren M., Kamischke A., et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. JClin Endocrinol Metab 2005, 90:6603-6608.
39. Kamischke A., Venherm S., Plöger D., et al. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. JClin Endocrinol Metab 2001, 86:303-309.
40. Larkin A. Male hormonal contraceptive trial ending early 2011. Available at:. Accessed May 17, 2013. http://www.conrad.org/news-pressreleases-63.html.
41. Foegh M., Damgaard-Pedersen F., Gormsen J., et al. Oral levo-norgestrel - testosterone effects on spermatogenesis, hormone levels, coagulation factors and lipoproteins in normal men. Contraception 1980, 21:381-391.
42. Bain J., Rachlis V., Robert E., et al. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme. Contraception 1980, 21:365-379.
43. Amory J.K., Bush M.A., Zhi H., et al. Oral testosterone with and without concomitant inhibition of 5alpha-reductase by dutasteride in hypogonadal men for 28 days. JUrol 2011, 185:626-632.
44. Meriggiola M.C., Bremner W.J., Costantino A., et al. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril 1997, 68:844-850.
45. Vest S.A., Howard J.E. Clinical experiments with androgens: IV. A method of implantation of crystalline testosterone. JAm Med Assoc 1939, 113:1869-1872.
46. Handelsman D.J., Conway A.J., Boylan L.M. Suppression of human spermatogenesis by testosterone implants. JClin Endocrinol Metab 1992, 75:1326-1332.
47. Handelsman D.J., Conway A.J., Howe C.J., et al. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. JClin Endocrinol Metab 1996, 81:4113-4121.
48. Handelsman D.J., Conway A.J., Boylan L.M. Pharmacokinetics and pharmacodynamics of testosterone pellets in man. JClin Endocrinol Metab 1990, 71:216-222.
49. Handelsman D.J., Wishart S., Conway A.J. Oestradiol enhances testosterone-induced suppression of human spermatogenesis. Hum Reprod 2000, 15:672-679.
50. Martin C.W., Riley S.C., Everington D., et al. Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men. Hum Reprod 2000, 15:1515-1524.
51. Kinniburgh D., Anderson R.A., Baird D.T. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. JAndrol 2001, 22:88-95.
52. Brady B.M., Walton M., Hollow N., et al. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod 2004, 19:2658-2667.
53. Pollanen P., Nikkanen V., Huhtaniemi I. Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int J Androl 2001, 24:369-380.
54. Büchter D., von Eckardstein S., von Eckardstein A., et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. JClin Endocrinol Metab 1999, 84:1244-1249.
55. Ilani N., Roth M.Y., Amory J.K., et al. Anew combination of testosterone and nestorone transdermal gels for male hormonal contraception. JClin Endocrinol Metab 2012, 97:3476-3486.
56. Page S.T., Amory J.K., Anawalt B.D., et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. JClin Endocrinol Metab 2006, 91:4374-4380.
57. Rabin D., Evans R.M., Alexander A.N., et al. Heterogeneity of sperm density profiles following 20-week therapy with high-dose LHRH analog plus testosterone. JAndrol 1984, 5:176-180.
58. Behre H.M., Nashan D., Hubert W., et al. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. JClin Endocrinol Metab 1992, 74:84-90.
59. Linde R., Doelle G.C., Alexander N., et al. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. NEngl J Med 1981, 305:663-667.
60. Bagatell C.J., Matsumoto A.M., Christensen R.B., et al. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. JClin Endocrinol Metab 1993, 77:427-432.
61. Swerdloff R.S., Bagatell C.J., Wang C., et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. JClin Endocrinol Metab 1998, 83:3527-3533.
62. Behre H.M., Kliesch S., Lemcke B., et al. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 2001, 16:2570-2577.
63. Page S.T., Amory J.K., Bremner W.J. Advances in male contraception. Endocr Rev 2008, 29:465-493.
64. von Eckardstein S., Noe G., Brache V., et al. Aclinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. JClin Endocrinol Metab 2003, 88:5232-5239.
65. Walton M.J., Kumar N., Baird D.T., et al. 7alpha-methyl-19-nortestosterone (MENT) vs testosterone in combination with etonogestrel implants for spermatogenic suppression in healthy men. JAndrol 2007, 28:679-688.
66. Nieschlag E., Kumar N., Sitruk-Ware R. 7alpha-Methyl-19-nortestosterone (MENTR): the Population Council's contribution to research on male contraception and treatment of hypogonadism. Contraception 2013, 87:288-295.
67. Liu P.Y., Swerdloff R.S., Anawalt B.D., et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. JClin Endocrinol Metab 2008, 93:1774-1783.
68. Ilani N., Swerdloff R.S., Wang C. Male hormonal contraception: potential risks and benefits. Rev Endocr Metab Disord 2011, 12:107-117.
69. Mommers E., Kersemaekers W.M., Elliesen J., et al. Male hormonal contraception: a double-blind, placebo-controlled study. JClin Endocrinol Metab 2008, 93:2572-2580.
70. Fernández-Balsells M.M., Murad M.H., Lane M., et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. JClin Endocrinol Metab 2010, 95:2560-2575.
71. Liu G.Z., Lyle K.C. Clinical trial of gossypol as a male contraceptive drug. Part II. Hypokalemia study. Fertil Steril 1987, 48:462-465.
72. Liu G.Z., Lyle K.C., Cao J. Clinical trial of gossypol as a male contraceptive drug. Part I. Efficacy study. Fertil Steril 1987, 48:459-461.
73. Gossypol-a new antifertility agent for males. Gynecol Obstet Invest 1979, 10:163-176.
74. Waites G.M., Wang C., Griffin P.D. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int J Androl 1998, 21:8-12.
75. Zhen Q.S., Ye X., Wei Z.J. Recent progress in research on tripterygium - a male antifertility plant. Contraception 1995, 51:121-129.
76. Lue Y.H., Hikim A.P., Wang C., et al. Triptolide: a potential male contraceptive. JAndrol 1998, 19:479-486.
77. Huynh P.N., Hikim A.P., Wang C., et al. Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. JAndrol 2000, 21:689-699.
78. Qian S.Z. Tripterygium wilfordii, a Chinese herb effective in male fertility regulation. Contraception 1987, 36:335-345.
79. Vickery B.H. Non-steroidal interference with male fertility. Adv Contracept 1986, 2:1-30.
80. Hild S.A., Marshall G.R., Attardi B.J., et al. Development of l-CDB-4022 as a nonsteroidal male oral contraceptive: induction and recovery from severe oligospermia in the adult male cynomolgus monkey (Macaca fascicularis). Endocrinology 2007, 148:1784-1796.
81. Mok K.W., Mruk D.D., Lie P.P., et al. Adjudin, a potential male contraceptive, exerts its effects locally in the seminiferous epithelium of mammalian testes. Reproduction 2011, 141:571-580.
82. Cheng C.Y., Silvestrini B., Grima J., et al. Two new male contraceptives exert their effects by depleting germ cells prematurely from the testis. Biol Reprod 2001, 65:449-461.
83. Mruk D.D., Wong C.H., Silvestrini B., et al. Amale contraceptive targeting germ cell adhesion. Nat Med 2006, 12:1323-1328.
84. Tash J.S., Attardi B., Hild S.A., et al. Anovel potent indazole carboxylic acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biol Reprod 2008, 78:1127-1138.
85. Wolbach S.B., Howe P.R. Tissue changes following deprivation of fat-soluble A vitamin. JExp Med 1925, 42:753-777.
86. Coulston F., Beyler A.L., Drobeck H.P. The biologic actions of a new series of Bis(dichloroacetyel) diamines. Toxicol Appl Pharmacol 1960, 2:715-731.
87. Heller C.G., Moore D.J., Paulsen C.A. Suppression of spermatogenesis and chronic toxicity in men by a new series of Bis(dichloroacetyel) diamines. Toxicol Appl Pharmacol 1961, 3:1-7.
88. Amory J.K., Muller C.H., Shimshoni J.A., et al. Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. JAndrol 2011, 32:111-119.
89. Hogarth C.A., Evanoff R., Snyder E., et al. Suppression of Stra8 expression in the mouse gonad by WIN 18,446. Biol Reprod 2011, 84:957-965.
90. Anderson E.L., Baltus A.E., Roepers-Gajadien H.L., et al. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. Proc Natl Acad Sci U S A 2008, 105:14976-14980.
91. Hogarth C.A., Evanoff R., Mitchell D., et al. Turning a spermatogenic wave into a tsunami: synchronizing murine spermatogenesis using WIN 18,446. Biol Reprod 2013, 88:40.
92. Schulze G.E., Clay R.J., Mezza L.E., et al. BMS-189453, a novel retinoid receptor antagonist, is a potent testicular toxin. Toxicol Sci 2001, 59:297-308.
93. Chung S.S., Wang X., Roberts S.S., et al. Oral administration of a retinoic acid receptor antagonist reversibly inhibits spermatogenesis in mice. Endocrinology 2011, 52:2492-2502.
94. Lishko P.V., Kirichok Y., Ren D., et al. The control of male fertility by spermatozoan ion channels. Annu Rev Physiol 2012, 74:453-475.
95. Hershlag A., Cooper G.W., Benoff S. Pregnancy following discontinuation of a calcium channel blocker in the male partner. Hum Reprod 1995, 10:599-606.
96. Katsoff D., Check J.H. Achallenge to the concept that the use of calcium channel blockers causes reversible male infertility. Hum Reprod 1997, 12:1480-1482.
97. Qi H., MOran M.M., Navarro B., et al. All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility. Proc Natl Acad Sci U S A 2007, 104:1219-1223.
98. Ren D.J., Navarro B., Perez G., et al. Asperm ion channel required for sperm motility and male fertility. Nature 2001, 413:603-609.
99. Carlson A.E., Burnett L.A., del Camino D., et al. Pharmacological targeting of native CatSper channels reveals a required role in maintenance of sperm hyperactivation. PLoS One 2009, 4:e6844.
100. Li H., Ding X., Guo C., et al. Immunization of male mice with B-cell epitopes in transmembrane domains of CatSper1 inhibits fertility. Fertil Steril 2012, 97:445-452.
101. Wang D., King S.M., Quill T.A., et al. Anew sperm-specific Na+/H+ exchanger required for sperm motility and fertility. Nat Cell Biol 2003, 5:1117-1122.
102. Wang D., Hu J., Bobulescu I.A., et al. Asperm-specific Na+/H+ exchanger (sNHE) is critical for expression and invivo bicarbonate regulation of the soluble adenylyl cyclase (sAC). Proc Natl Acad Sci U S A 2007, 104:9325-9330.
103. van der Spoel A.C., Jeyakumar M., Butters T.D., et al. Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A 2002, 99:17173-17178.
104. Walden C.M., Butters T.D., Dwek R.A., et al. Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin. Hum Reprod 2006, 21:1309-1315.
105. Amory J.K., Muller C.H., Page S.T., et al. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod 2007, 22:702-707.
106. Shang E., Nickerson H.D., Wen D., et al. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 2007, 134:3507-3515.
107. Aston K.I., Krausz C., Laface I., et al. Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Hum Reprod 2010, 25:1383-1397.
108. Gaucher J., Boussouar F., Montellier E., et al. Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J 2012, 31:3809-3820.
109. Matzuk M.M., McKeown M.R., Filippalopolous P., et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150:673-684.
110. Wang C., McDonald V., Leung A., et al. Effect of increased scrotal temperature on sperm production in normal men. Fertil Steril 1997, 68:334-339.
111. Wang C., Cui Y.G., Wang X.H., et al. Transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosis. JClin Endocrinol Metab 2007, 92:3292-3304.
112. Fahim M.S., Fahim Z., Harman J., et al. Ultrasound as a new method of male contraception. Fertil Steril 1977, 28:823-831.
113. Fahim M.S., Fahim Z., Der R., et al. Heat in male contraception (hot water 60 degrees C, infrared, microwave, and ultrasound). Contraception 1975, 11:549-562.
114. Dumontier A., Burdick A., Ewigman B., et al. Effects of sonication on mature rat testes. Fertil Steril 1977, 28:195-204.
115. Bailey K.I., Obrien W.D., Dunn F. Ultrasonically induced, invivo morphological damage in mouse testicular tissue. Arch Androl 1981, 6:301-306.
116. Urry R.L., Dougherty K.A., Child S.A., et al. Ultrasound and spermatogenesis in the rat. Ultrasound Med Biol 1988, 14:213-217.
117. Tsuruta J.K., Dayton P.A., Gallippi C.M., et al. Therapeutic ultrasound as a potential male contraceptive: power, frequency and temperature required to deplete rat testes of meiotic cells and epididymides of sperm determined using a commercially available system. Reprod Biol Endocrinol 2012, 10:7.
118. VandeVoort C.A., Tollner T.L. The efficacy of ultrasound treatment as a reversible male contraceptive in the rhesus monkey. Reprod Biol Endocrinol 2012, 10:81.
119. Lee H.Y. Experimental studies on reversible vas occlusion by intravasal thread. Fertil Steril 1969, 20:735-737.
120. Song L., Gu Y., Liang X., et al. Aphase II randomized controlled trial of a novel male contraception, an intra-vas device. Int J Androl 2006, 29:489-495.
121. Huang X.B., Suo J.P., Chen C.Y., et al. Initial studies on a novel filtering-type intra-vas device in male dogs. Contraception 2010, 81:350-354.
122. Chen Z.L., Huang X.B., Suo J.P., et al. The contraceptive effect of a novel filtering-type nano-copper complex/polymer composites intra-vas device on male animals. Int J Androl 2010, 33:810-817.
123. Misro M., Guha S.K., Singh H., et al. Injectable non-occlusive chemical contraception in the male-I. Contraception 1979, 20:467-473.
124. Guha S.K., Singh G., Ansari S., et al. Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 1997, 56:245-250.
125. Chaki S.P., Das H.C., Misro M.M. Ashort-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG. Contraception 2003, 67:73-78.
126. Lohiya N.K., Manivannan B., Mishra P.K., et al. Intravasal contraception with styrene maleic anhydride and its noninvasive reversal in langur monkeys (Presbytis entellus entellus). Contraception 1998, 58:119-128.
127. Mishra P.K., Manivannan B., Pathak N., et al. Status of spermatogenesis and sperm parameters in langur monkeys following long-term maleic anhydride vas occlusion with styrene. JAndrol 2003, 24:501-509.
128. Lohiya N.K., Manivannan B., Mishra P.K., et al. Preclinical evaluation for noninvasive reversal following long-term vas occlusion with styrene maleic anhydride in langur monkeys. Contraception 2005, 71:214-226.
129. Lohiya N.K., Suthar R., Khandelwal A., et al. Sperm characteristics and teratology in rats following vas deferens occlusion with RISUG and its reversal. Int J Androl 2010, 33:e198-e206.
130. Ansari A.S., Alam I., Hussain M., et al. Evaluation of genotoxicity in leukocytes and testis following intra-vasal contraception with RISUG and its reversal by DMSO and NaHCO3 in Wistar albino rats. Reprod Toxicol 2013, 36:53-59.
131. Beck M. Honey, it's your turn. Wall Street Journal 2011, Available at:. http://online.wsj.com/article/SB10001424052702303848104576383730320049892.html.
132. Gifford B. The revolutionary new birth control method for men. 2011. Available at:. Accessed May 22, 2013. http://www.wired.com/magazine/2011/04/ff_vasectomy/all/.
133. Henle W., Henle G., Chambers L.A. Studies on the antigenic structure of some mammalian spermatozoa. JExp Med 1938, 68:335-352.
134. Kummerfeld H.L., Foote R.H. Infertility and embryonic mortality in female rabbits immunized with different sperm preparations. Biol Reprod 1976, 14:300-305.
135. Munoz M.G., Metz C.B. Infertility in female rabbits isoimmunized with subcellular sperm fractions. Biol Reprod 1978, 18:669-678.
136. Isojima S., Graham R.M., Graham J.B. Sterility in female guinea pigs induced by injection with testis. Science 1959, 129:44.
137. Menge A.C., Peegel H., Riolo M.L. Sperm fractions responsible for immunological induction of pre-fertilization and post-fertilization in rabbits. Biol Reprod 1979, 20:931-937.
138. Fuchs E.F., Alexander N.J. Immunologic considerations before and after vasovasostomy. Fertil Steril 1983, 40:497-499.
139. Primakoff P., Lathrop W., Woolman L., et al. Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20. Nature 1988, 335:543-546.
140. Tung K.S., Primakoff P., Woolman-Gamer L., et al. Mechanism of infertility in male guinea pigs immunized with sperm PH-20. Biol Reprod 1997, 56:1133-1141.
141. Wang Z.J., Widgren E.E., Sivashanmugam P., et al. Association of Eppin with semenogelin on human spermatozoa. Biol Reprod 2005, 72:1064-1070.
142. De Lamirande E., Yoshida K., Yoshiike T.M., et al. Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process. JAndrol 2001, 22:672-679.
143. O'Rand M.G., Widgren E.E., Sivashanmugam P., et al. Reversible immunocontraception in male monkeys immunized with Eppin. Science 2004, 306:1189-1190.
144. O'Rand M.G., Widgren E.E., Beyler S., et al. Inhibition of human sperm motility by contraceptive anti-eppin antibodies from infertile male monkeys: effect on cyclic adenosine monophosphate. Biol Reprod 2009, 80:279-285.
145. O'Rand M.G., Widgren E.E. Loss of calcium in human spermatozoa via EPPIN, the semenogelin receptor. Biol Reprod 2012, 86:55.
146. Silva E.J., Hamil K.G., Richardson R.T., et al. Characterization of EPPIN's semenogelin I binding site: a contraceptive drug target. Biol Reprod 2012, 87:56.
147. Mitra A., Richardson R.T., O'Rand M.G. Analysis of recombinant human semenogelin as an inhibitor of human sperm motility. Biol Reprod 2010, 82:489-496.
148. Goodman A. The long wait for male birth control. Time 2008, Available at:. http://content.time.com/time/health/article/0,8599,1829107,00.html.
149. Piccinino L.J., Mosher W.D. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998, 30:4-10.
150. Glasier A.F., Anakwe R., Everington D., et al. Would women trust their partners to use a male pill?. Hum Reprod 2000, 15:646-649.